Mesoblast (MESO) announced its addition to the S&P Dow Jones Indices’ S&P/ASX 200 Index effective March 6, 2025 on the Australian Stock Exchange.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO:
- Mesoblast’s Earnings Call: RYONCIL Approval & Growth
- Buy Rating for Mesoblast Driven by Promising Market Position and Strong Financial Backing
- Mesoblast Reports FDA Approval and Financial Results
- Mesoblast Appoints Dr. Gregory George to Board, Enhancing Strategic and Operational Expertise
- Mesoblast price target raised to $24 from $15 at Piper Sandler